{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:37:15Z","timestamp":1793824635317,"version":"4.6.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K09616"],"award-info":[{"award-number":["21K09616"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K07417"],"award-info":[{"award-number":["20K07417"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K06432"],"award-info":[{"award-number":["23K06432"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K07597"],"award-info":[{"award-number":["20K07597"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K06939"],"award-info":[{"award-number":["22K06939"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K165681"],"award-info":[{"award-number":["19K165681"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K06969"],"award-info":[{"award-number":["22K06969"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K16835"],"award-info":[{"award-number":["21K16835"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s00428-023-03598-3","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T01:02:26Z","timestamp":1689728546000},"page":"367-379","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prognostic value and clinicopathological roles of the tumor immune microenvironment in salivary duct carcinoma"],"prefix":"10.1007","volume":"483","author":[{"given":"Hideaki","family":"Hirai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6987-3043","authenticated-orcid":false,"given":"Masato","family":"Nakaguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0159-8660","authenticated-orcid":false,"given":"Yuichiro","family":"Tada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuki","family":"Saigusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3794-2790","authenticated-orcid":false,"given":"Daisuke","family":"Kawakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Honma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoaki","family":"Tsukahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuro","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Okami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Urano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manami","family":"Kajiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Utsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomotaka","family":"Shimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Fushimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahito","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yorihisa","family":"Imanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Togashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyoyuki","family":"Hanazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Matsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuto","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2075-9738","authenticated-orcid":false,"given":"Toshitaka","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,19]]},"reference":[{"key":"3598_CR1","unstructured":"Chiosea S, Agaimy A, Nagao T, et al. (2022) Salivary duct carcinoma. In: WHO Classification of Tumours Online, Head and Neck Tumours (WHO Classification of tumours series, 5th ed.; vol.9). https:\/\/tumourclassification.iarc.who.int\/chapters\/52. Accessed 19 June 2023."},{"key":"3598_CR2","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/cncy.22288","volume":"128","author":"M Nakaguro","year":"2020","unstructured":"Nakaguro M, Tada Y, Faquin WC et al (2020) Salivary duct carcinoma: Updates in histology, cytology, molecular biology, and treatment. Cancer Cytopathol 128:693\u2013703. https:\/\/doi.org\/10.1002\/cncy.22288","journal-title":"Cancer Cytopathol"},{"key":"3598_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10147-014-0674-6","volume":"20","author":"T Masubuchi","year":"2015","unstructured":"Masubuchi T, Tada Y, Maruya S-i et al (2015) Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma. Int J Clin Oncol 20:35\u201344. https:\/\/doi.org\/10.1007\/s10147-014-0674-6","journal-title":"Int J Clin Oncol"},{"key":"3598_CR4","doi-asserted-by":"publisher","first-page":"59023","DOI":"10.18632\/oncotarget.19812","volume":"8","author":"S Takase","year":"2017","unstructured":"Takase S, Kano S, Tada Y et al (2017) Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification. Oncotarget 8:59023\u201359035. https:\/\/doi.org\/10.18632\/oncotarget.19812","journal-title":"Oncotarget"},{"key":"3598_CR5","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/annonc\/mdx771","volume":"29","author":"C Fushimi","year":"2018","unstructured":"Fushimi C, Tada Y, Takahashi H et al (2018) A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. Ann Oncol 29:979\u2013984. https:\/\/doi.org\/10.1093\/annonc\/mdx771","journal-title":"Ann Oncol"},{"key":"3598_CR6","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/hed.25035","volume":"40","author":"E Boon","year":"2018","unstructured":"Boon E, van Boxtel W, Buter J et al (2018) Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands. Head Neck 40:605\u2013613. https:\/\/doi.org\/10.1002\/hed.25035","journal-title":"Head Neck"},{"key":"3598_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1200\/jco.18.00545","volume":"37","author":"H Takahashi","year":"2019","unstructured":"Takahashi H, Tada Y, Saotome T et al (2019) Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma. J Clin Oncol 37:125\u2013134. https:\/\/doi.org\/10.1200\/jco.18.00545","journal-title":"J Clin Oncol"},{"key":"3598_CR8","doi-asserted-by":"publisher","first-page":"16988","DOI":"10.1038\/s41598-020-73965-6","volume":"10","author":"K Niwa","year":"2020","unstructured":"Niwa K, Kawakita D, Nagao T et al (2020) Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma. Sci Rep 10:16988. https:\/\/doi.org\/10.1038\/s41598-020-73965-6","journal-title":"Sci Rep"},{"key":"3598_CR9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ejca.2022.05.007","volume":"171","author":"C Even","year":"2022","unstructured":"Even C, Delord JP, Price KA et al (2022) Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study. Eur J Cancer 171:259\u2013268. https:\/\/doi.org\/10.1016\/j.ejca.2022.05.007","journal-title":"Eur J Cancer"},{"key":"3598_CR10","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/s1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J et al (2020) Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 21:1353\u20131365. https:\/\/doi.org\/10.1016\/s1470-2045(20)30445-9","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"3598_CR11","doi-asserted-by":"publisher","first-page":"6083","DOI":"10.1200\/JCO.2019.37.15_suppl.6083","volume":"37","author":"J Fayette","year":"2019","unstructured":"Fayette J, Even C, Digue L et al (2019) NISCAHN: A phase II, multicenter nonrandomized trial aiming at evaluating nivolumab (N) in two cohorts of patients (pts) with recurrent\/metastatic (R\/M) salivary gland carcinoma of the head and neck (SGCHN), on behalf of the Unicancer Head & Neck Group. J Clin Oncol 37(15_suppl):6083. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.6083","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"3598_CR12","doi-asserted-by":"publisher","first-page":"6084","DOI":"10.1200\/JCO.2019.37.15_suppl.6084","volume":"37","author":"V Tchekmedyian","year":"2019","unstructured":"Tchekmedyian V, Sherman EJ, Dunn L et al (2019) A phase II trial cohort of nivolumab plus ipilimumab in patients (Pts) with recurrent\/metastatic adenoid cystic carcinoma (R\/M ACC). J Clin Oncol 37(15_suppl):6084. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.6084","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"3598_CR13","doi-asserted-by":"publisher","first-page":"6002","DOI":"10.1200\/JCO.2021.39.15_suppl.6002","volume":"39","author":"B Burman","year":"2021","unstructured":"Burman B, Sherman EJ, Dunn L et al (2021) A phase II trial cohort of nivolumab plus ipilimumab in patients (Pts) with recurrent\/metastatic salivary gland cancers (R\/M SGCs). J Clin Oncol 39(15_suppl):6002. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.6002","journal-title":"J Clin Oncol"},{"key":"3598_CR14","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1097\/COC.0000000000000429","volume":"41","author":"RB Cohen","year":"2018","unstructured":"Cohen RB, Delord J-P, Doi T et al (2018) Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study. Am J Clin Oncol 41:1083\u20131088. https:\/\/doi.org\/10.1097\/COC.0000000000000429","journal-title":"Am J Clin Oncol"},{"key":"3598_CR15","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1158\/1078-0432.CCR-19-2214","volume":"26","author":"CP Rodriguez","year":"2020","unstructured":"Rodriguez CP, Wu Q, Voutsinas J et al (2020) A phase II trial of pembrolizumab and vorinostat in recurrent metastatic head and neck squamous cell carcinomas and salivary gland cancer. Clin Cancer Res 26:837\u2013845. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2214","journal-title":"Clin Cancer Res"},{"key":"3598_CR16","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/jop.12722","volume":"47","author":"F Sato","year":"2018","unstructured":"Sato F, Akiba J, Kawahara A et al (2018) The expression of programed death ligand-1 could be related with unfavorable prognosis in salivary duct carcinoma. J Oral Pathol Med 47:683\u2013690. https:\/\/doi.org\/10.1111\/jop.12722","journal-title":"J Oral Pathol Med"},{"key":"3598_CR17","doi-asserted-by":"publisher","first-page":"981","DOI":"10.21873\/anticanres.15558","volume":"42","author":"K Hashimoto","year":"2022","unstructured":"Hashimoto K, Yasumatsu R, Kuga R et al (2022) Treatment Efficacy of PD-1 Inhibitor Therapy in Patients With Recurrent and\/or Metastatic Salivary Gland Carcinoma. Anticancer Res 42:981\u2013989. https:\/\/doi.org\/10.21873\/anticanres.15558","journal-title":"Anticancer Res"},{"key":"3598_CR18","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K et al (2018) Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 24:541\u2013550. https:\/\/doi.org\/10.1038\/s41591-018-0014-x","journal-title":"Nat Med"},{"key":"3598_CR19","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s12105-023-01528-y","volume":"17","author":"MV Veneroni","year":"2023","unstructured":"Veneroni MV, Festa BM, Costantino A et al (2023) Prognostic Impact of Tumor Immune Microenvironment and Its Predictive Role in Salivary Gland Cancer. Head Neck Pathol. https:\/\/doi.org\/10.1007\/s12105-023-01528-y","journal-title":"Head Neck Pathol"},{"key":"3598_CR20","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","volume":"14","author":"WH Fridman","year":"2017","unstructured":"Fridman WH, Zitvogel L, Saut\u00e8s-Fridman C et al (2017) The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol 14:717\u2013734. https:\/\/doi.org\/10.1038\/nrclinonc.2017.101","journal-title":"Nat Rev Clin Oncol"},{"key":"3598_CR21","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252\u2013264. https:\/\/doi.org\/10.1038\/nrc3239","journal-title":"Nat Rev Cancer"},{"key":"3598_CR22","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1097\/pai.0000000000000575","volume":"26","author":"L Chang","year":"2018","unstructured":"Chang L, Chang M, Chang HM et al (2018) Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy. Appl Immunohistochem Mol Morphol 26:e15\u2013e21. https:\/\/doi.org\/10.1097\/pai.0000000000000575","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"3598_CR23","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s12105-022-01486-x","volume":"17","author":"S Gerdabi","year":"2022","unstructured":"Gerdabi S, Asadian F, Kiani R et al (2022) Simultaneous Expression of PD-1 and PD-L1 in Peripheral and Central Immune Cells and Tumor Cells in the Benign and Malignant Salivary Gland Tumors Microenvironment. Head Neck Pathol. https:\/\/doi.org\/10.1007\/s12105-022-01486-x","journal-title":"Head Neck Pathol"},{"key":"3598_CR24","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/hed.26587","volume":"43","author":"G Schvartsman","year":"2021","unstructured":"Schvartsman G, Bell D, Rubin ML et al (2021) The tumor immune contexture of salivary duct carcinoma. Head Neck 43:1213\u20131219. https:\/\/doi.org\/10.1002\/hed.26587","journal-title":"Head Neck"},{"key":"3598_CR25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.anndiagpath.2019.04.001","volume":"40","author":"A Hamza","year":"2019","unstructured":"Hamza A, Roberts D, Su S et al (2019) PD-L1 expression by immunohistochemistry in salivary duct carcinoma. Ann Diagn Pathol 40:49\u201352. https:\/\/doi.org\/10.1016\/j.anndiagpath.2019.04.001","journal-title":"Ann Diagn Pathol"},{"key":"3598_CR26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.oraloncology.2019.01.015","volume":"90","author":"T Nakano","year":"2019","unstructured":"Nakano T, Takizawa K, Uezato A et al (2019) Prognostic value of programed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas. Oral Oncol 90:30\u201337. https:\/\/doi.org\/10.1016\/j.oraloncology.2019.01.015","journal-title":"Oral Oncol"},{"key":"3598_CR27","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1158\/1078-0432.ccr-19-3758","volume":"26","author":"M Linxweiler","year":"2020","unstructured":"Linxweiler M, Kuo F, Katabi N et al (2020) The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype. Clin Cancer Res 26:2859\u20132870. https:\/\/doi.org\/10.1158\/1078-0432.ccr-19-3758","journal-title":"Clin Cancer Res"},{"key":"3598_CR28","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/hed.26529","volume":"43","author":"E Guazzo","year":"2021","unstructured":"Guazzo E, Cooper C, Wilkinson L et al (2021) Therapeutic implications of immune-profiling and EGFR expression in salivary gland carcinoma. Head Neck 43:768\u2013777. https:\/\/doi.org\/10.1002\/hed.26529","journal-title":"Head Neck"},{"key":"3598_CR29","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3390\/cancers12040873","volume":"12","author":"HM Witte","year":"2020","unstructured":"Witte HM, Gebauer N, Lapp\u00f6hn D et al (2020) Prognostic Impact of PD-L1 Expression in Malignant Salivary Gland Tumors as Assessed by Established Scoring Criteria: Tumor Proportion Score (TPS), Combined Positivity Score (CPS), and Immune Cell (IC) Infiltrate. Cancers (Basel) 12:873. https:\/\/doi.org\/10.3390\/cancers12040873","journal-title":"Cancers (Basel)"},{"key":"3598_CR30","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1200\/jco.21.00449","volume":"39","author":"JL Geiger","year":"2021","unstructured":"Geiger JL, Ismaila N, Beadle B et al (2021) Management of Salivary Gland Malignancy: ASCO Guideline. J Clin Oncol 39:1909\u20131941. https:\/\/doi.org\/10.1200\/jco.21.00449","journal-title":"J Clin Oncol"},{"key":"3598_CR31","unstructured":"(2021) NCCN Clinical Practice Guidelines in Oncology, Head and Neck Cancers https:\/\/www.nccn.org\/professionals_gls\/default.aspx. Accessed February, 14 2020"},{"key":"3598_CR32","first-page":"47","volume-title":"TNM Classfication of Malignant Tumours","author":"JD Brierley","year":"2017","unstructured":"Brierley JD, Gospodarowicz MK, Wittekind C (2017) TNM Classfication of Malignant Tumours, 8th edn. Wiley-Blackwell, Hoboken, pp 47\u201349","edition":"8"},{"key":"3598_CR33","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/pap.0000000000000162","volume":"24","author":"S Hendry","year":"2017","unstructured":"Hendry S, Salgado R, Gevaert T et al (2017) Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Adv Anat Pathol 24:235\u2013251. https:\/\/doi.org\/10.1097\/pap.0000000000000162","journal-title":"Adv Anat Pathol"},{"key":"3598_CR34","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/PAS.0000000000001413","volume":"44","author":"M Nakaguro","year":"2020","unstructured":"Nakaguro M, Sato Y, Tada Y et al (2020) Prognostic Implication of Histopathologic Indicators in Salivary Duct Carcinoma: Proposal of a Novel Histologic Risk Stratification Model. Am J Surg Pathol 44:526\u2013535. https:\/\/doi.org\/10.1097\/PAS.0000000000001413","journal-title":"Am J Surg Pathol"},{"key":"3598_CR35","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1200\/jco.2016.68.1478","volume":"34","author":"LQM Chow","year":"2016","unstructured":"Chow LQM, Haddad R, Gupta S et al (2016) Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and\/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. J Clin Oncol 34:3838\u20133845. https:\/\/doi.org\/10.1200\/jco.2016.68.1478","journal-title":"J Clin Oncol"},{"key":"3598_CR36","doi-asserted-by":"publisher","first-page":"104931","DOI":"10.1016\/j.oraloncology.2020.104931","volume":"111","author":"N Kesar","year":"2020","unstructured":"Kesar N, Winkelmann R, Oppermann J et al (2020) Prognostic impact of CD8-positive tumour-infiltrating lymphocytes and PD-L1 expression in salivary gland cancer. Oral Oncol 111:104931. https:\/\/doi.org\/10.1016\/j.oraloncology.2020.104931","journal-title":"Oral Oncol"},{"key":"3598_CR37","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s13058-014-0432-8","volume":"16","author":"S Liu","year":"2014","unstructured":"Liu S, Foulkes WD, Leung S et al (2014) Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. Breast Cancer Res 16:432. https:\/\/doi.org\/10.1186\/s13058-014-0432-8","journal-title":"Breast Cancer Res"},{"key":"3598_CR38","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s12539-020-00358-8","volume":"12","author":"S Wu","year":"2020","unstructured":"Wu S, Liu X, Wang J et al (2020) DNA Mismatch Repair Deficiency Detection in Colorectal Cancer by a New Microsatellite Instability Analysis System. Interdiscip Sci 12:145\u2013154. https:\/\/doi.org\/10.1007\/s12539-020-00358-8","journal-title":"Interdiscip Sci"},{"key":"3598_CR39","doi-asserted-by":"publisher","first-page":"12724","DOI":"10.1038\/s41598-019-49215-9","volume":"9","author":"D Vital","year":"2019","unstructured":"Vital D, Ikenberg K, Moch H et al (2019) The expression of PD-L1 in salivary gland carcinomas. Sci Rep 9:12724\u201312724. https:\/\/doi.org\/10.1038\/s41598-019-49215-9","journal-title":"Sci Rep"},{"key":"3598_CR40","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.2147\/ott.s134589","volume":"10","author":"H Chang","year":"2017","unstructured":"Chang H, Kim JS, Choi YJ et al (2017) Overexpression of PD-L2 is associated with shorter relapse-free survival in patients with malignant salivary gland tumors. OncoTargets Ther 10:2983\u20132992. https:\/\/doi.org\/10.2147\/ott.s134589","journal-title":"OncoTargets Ther"},{"key":"3598_CR41","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","volume":"12","author":"EJ Wherry","year":"2011","unstructured":"Wherry EJ (2011) T cell exhaustion. Nat Immunol 12:492\u2013499. https:\/\/doi.org\/10.1038\/ni.2035","journal-title":"Nat Immunol"},{"key":"3598_CR42","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s00262-020-02551-6","volume":"69","author":"C Arolt","year":"2020","unstructured":"Arolt C, Meyer M, Ruesseler V et al (2020) Lymphocyte activation gene 3 (LAG3) protein expression on tumor-infiltrating lymphocytes in aggressive and TP53-mutated salivary gland carcinomas. Cancer Immunol Immunother 69:1363\u20131373. https:\/\/doi.org\/10.1007\/s00262-020-02551-6","journal-title":"Cancer Immunol Immunother"},{"key":"3598_CR43","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/his.13944","volume":"75","author":"B Xu","year":"2019","unstructured":"Xu B, Jungbluth AA, Frosina D et al (2019) The immune microenvironment and expression of PD-L1, PD-1, PRAME and MHC I in salivary duct carcinoma. Histopathology 75:672\u2013682. https:\/\/doi.org\/10.1111\/his.13944","journal-title":"Histopathology"},{"key":"3598_CR44","first-page":"3491","volume":"58","author":"Y Naito","year":"1998","unstructured":"Naito Y, Saito K, Shiiba K et al (1998) CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58:3491\u20133494","journal-title":"Cancer Res"},{"key":"3598_CR45","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.18632\/oncotarget.6231","volume":"7","author":"V Kotoula","year":"2016","unstructured":"Kotoula V, Chatzopoulos K, Lakis S et al (2016) Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials. Oncotarget 7:5074\u20135087. https:\/\/doi.org\/10.18632\/oncotarget.6231","journal-title":"Oncotarget"},{"key":"3598_CR46","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s12105-020-01163-x","volume":"14","author":"K Chatzopoulos","year":"2020","unstructured":"Chatzopoulos K, Collins AR, Sotiriou S et al (2020) Increased ERBB2 Gene Copy Numbers Reveal a Subset of Salivary Duct Carcinomas with High Densities of Tumor Infiltrating Lymphocytes and PD-L1 Expression. Head Neck Pathol 14:951\u2013965. https:\/\/doi.org\/10.1007\/s12105-020-01163-x","journal-title":"Head Neck Pathol"},{"key":"3598_CR47","doi-asserted-by":"publisher","first-page":"7322","DOI":"10.1002\/cam4.2602","volume":"8","author":"SM Gargano","year":"2019","unstructured":"Gargano SM, Senarathne W, Feldman R et al (2019) Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling. Cancer Med 8:7322\u20137329. https:\/\/doi.org\/10.1002\/cam4.2602","journal-title":"Cancer Med"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-023-03598-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-023-03598-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-023-03598-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T13:04:22Z","timestamp":1695992662000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-023-03598-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,19]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["3598"],"URL":"https:\/\/doi.org\/10.1007\/s00428-023-03598-3","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,19]]},"assertion":[{"value":"21 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed with ethical permission from the Institutional Ethics Review Board of each participating institution.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}